These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10882574)

  • 41. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The spread of the wild Poliovirus in the rural environment, the case of the Adzopé health district, Côte d'Ivoire].
    Akoua-Koffi CG; Nekouressi G; Tieoulou L; Guillot S; Faye-Kette H; Ehouman A
    Bull Soc Pathol Exot; 2004 May; 97(2):87-90. PubMed ID: 15255346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Poliovirus neutralizing antibody persistence after vaccination with the Sabin vaccine: a follow-up study.
    Farisano G; Trivello R; Moschen ME; Bonello C; Baldo V; Moretti G; Majori S; Marin F; Piron L; Renzulli G
    Ann Clin Lab Sci; 1995; 25(2):200-6. PubMed ID: 7785968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses.
    Muller DA; Pearson FE; Fernando GJ; Agyei-Yeboah C; Owens NS; Corrie SR; Crichton ML; Wei JC; Weldon WC; Oberste MS; Young PR; Kendall MA
    Sci Rep; 2016 Feb; 6():22094. PubMed ID: 26911254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S; Friedland LR; Schuind A; Howe B;
    Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucosal immune response to poliovirus vaccines in childhood.
    Ogra PL
    Rev Infect Dis; 1984; 6 Suppl 2():S361-8. PubMed ID: 6740074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secretory IgA and IgM antibodies to E. coli O and poliovirus type I antigens occur in amniotic fluid, meconium and saliva from newborns. A neonatal immune response without antigenic exposure: a result of anti-idiotypic induction?
    Mellander L; Carlsson B; Hanson LA
    Clin Exp Immunol; 1986 Mar; 63(3):555-61. PubMed ID: 3011325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
    Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune response to oral polio vaccine in patients with IgA glomerulonephritis.
    Leinikki PO; Mustonen J; Pasternack A
    Clin Exp Immunol; 1987 Apr; 68(1):33-8. PubMed ID: 2820631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
    Minor PD; Dunn G; Ramsay ME; Brown D
    J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus.
    Ogra PL
    N Engl J Med; 1971 Jan; 284(2):59-64. PubMed ID: 4321186
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
    Rezapkin G; Dragunsky E; Chumakov K
    Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.